Kalshi Launches Prediction Markets for Drug Development
Kalshi has launched new markets focused on clinical trials and FDA decisions. The company believes the markets could accelerate drug development, but researchers warn of potential risks.
Financial technology company Kalshi launched new prediction markets on Thursday, centering on phases of drug development such as clinical trials and regulatory decisions from the U.S. Food and Drug Administration (FDA).
The company suggests that public access to the odds of drug development projects could speed up research and contribute to the creation of new medicines. Kalshi's chief communications officer, Jack Such, stated that at this early stage, there is no evidence yet on the markets' actual impact on development.
However, concerns regarding valuation risks have been raised. Researchers, including Jonathan Kimmelman, a professor of biomedical ethics at McGill University, have expressed apprehension that these markets might direct funding toward already favored projects or potentially increase incentives for scientific misconduct, especially if the success of specific drug candidates is directly tied to market outcomes.
The FDA has previously reported a significant number of studies with unposted results, highlighting information flow challenges in the sector. Kalshi's markets aim to surface distributed information and provide signals for pharmaceutical companies to identify underperforming programs.